Search by Drug Name or NDC
NDC 62332-0160-30 Pramipexole Dihydrochloride 3.75 mg/1 Details
Pramipexole Dihydrochloride 3.75 mg/1
Pramipexole Dihydrochloride is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Alembic Pharmaceuticals Inc.. The primary component is PRAMIPEXOLE DIHYDROCHLORIDE.
MedlinePlus Drug Summary
Pramipexole is used alone or with other medications to treat the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance), including shaking of parts of the body, stiffness, slowed movements, and problems with balance. Pramipexole is also used to treat restless legs syndrome (RLS; a condition that causes discomfort in the legs and a strong urge to move the legs, especially at night and when sitting or lying down). Pramipexole is in a class of medications called dopamine agonists. It works by acting in place of dopamine, a natural substance in the brain that is needed to control movement.
Related Packages: 62332-0160-30Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Pramipexole
Product Information
| NDC | 62332-0160 |
|---|---|
| Product ID | 62332-160_180f524e-cf28-4ede-b70c-07a004f7460e |
| Associated GPIs | |
| GCN Sequence Number | 067523 |
| GCN Sequence Number Description | pramipexole di-HCl TAB ER 24H 3.75 MG ORAL |
| HIC3 | H6A |
| HIC3 Description | ANTIPARKINSONISM DRUGS,OTHER |
| GCN | 30102 |
| HICL Sequence Number | 013455 |
| HICL Sequence Number Description | PRAMIPEXOLE DI-HCL |
| Brand/Generic | Generic |
| Proprietary Name | Pramipexole Dihydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Pramipexole Dihydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 3.75 |
| Active Ingredient Units | mg/1 |
| Substance Name | PRAMIPEXOLE DIHYDROCHLORIDE |
| Labeler Name | Alembic Pharmaceuticals Inc. |
| Pharmaceutical Class | Dopamine Agonists [MoA], Nonergot Dopamine Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA204518 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 62332-0160-30 (62332016030)
| NDC Package Code | 62332-160-30 |
|---|---|
| Billing NDC | 62332016030 |
| Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (62332-160-30) |
| Marketing Start Date | 2019-01-03 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |